Le Lézard
Classified in: Health
Subjects: RCL, PSF

Advisory - Baxter recalls two lots of Extraneal peritoneal dialysis solution because of high levels of sodium hypochlorite, which may pose serious health risks


OTTAWA, March 23, 2019 /CNW/ - Health Canada is advising Canadians that Baxter Corporation is voluntarily recalling two lots of Extraneal peritoneal dialysis solution as a precautionary measure because of high levels of sodium hypochlorite.

Use of the affected product in patients could cause chemical peritonitis. Chemical peritonitis is inflammation of the peritoneum (the lining of the abdomen and pelvis), which can be serious if not promptly treated. Symptoms include nausea, vomiting, and abdominal pain or tenderness. The high levels of sodium hypochlorite are found in the active pharmaceutical ingredient icodextrin, and can cause discolouration of the solution.

Extraneal is a sterile peritoneal dialysis solution used for patients whose kidneys are not working properly. The dialysis solution is used in hospitals and home settings. The lots affected by this recall were distributed by Baxter between March 14, 2019 and March 20, 2019.

Who is affected
Canadians who have product from the affected lots

Affected products

 

Product

DIN

Product Code

Lot

Expiry

Extraneal 2L/2L Twinbag

02240806

JB9912

W9B28T0

02/29/2020

Extraneal 7.5% 2.5L SYSII

02240806

JB9923LP

W9C05T1

03/31/2020

 

What consumers should do

What Health Canada is doing
Health Canada is monitoring the recall. Should Health Canada become aware of additional safety information, it will take appropriate action and inform Canadians as necessary.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 11:40
The "Musculoskeletal Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the...

at 11:30
The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024....



News published on and distributed by: